Inverse system perturbations as a new methodology for identifying transcriptomic signaling participants in balanced biological processes

Cell Cycle

Volumn 8, Issue 17, 2009, Pages 2718-2722

  Hauser, Kai ^a,b   Abdollahi, Amir ^a,c   Huber, Peter E ^a,d  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b TECHNISCHE UNIVERSITÄT BERLIN   (Germany)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Angiogenesis; Angiogenic switch; Balanced homeostatic system; Pancreatic cancer; Signaling network; System perturbation; Transcriptomics

Indexed keywords

ANGIOGENESIS; CANCER GROWTH; GENE CONTROL; GENE REGULATORY NETWORK; HOMEOSTASIS; PANCREAS CANCER; PHENOTYPE; REVIEW; SIGNAL TRANSDUCTION; SPECTRUM; TRANSCRIPTOMICS;

EID: 69749126765     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.17.9401     Document Type: Review

References (21)

1. Wilkins AS. Genetic networks as transmitting and amplifying devices for natural genetic tinkering. Novartis Found Symp 2007; 284:71-86.
2. Folkman J, Kalluri R. Cancer without disease. Nature 2004; 427:787.
3. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438:932-936
4. Krammer PH. CD95's deadly mission in the immune system. Nature 2000; 407:789-795
5. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994; 331:1286-1292 (Pubitemid 24333194)
6. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
7. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88:277-285 (Pubitemid 28015876)
8. Abdollahi A, Hahnfeldt P, Maercker C, Grone HJ, Debus J, Ansorge W, et al. Endostatin's antiangiogenic signaling network. Mol Cell 2004; 13:649-663
9. Abdollahi A, Schwager C, Kleeff J, Esposito I, Domhan S, Peschke P, et al. Transcriptional network governing the angiogenic switch in human pancreatic carcinoma. PNAS 2007; 104:12890-12895 (Pubitemid 47255250)
10. Huber PE, Bischof M, Jenne J, Heiland S, Peschke P, Saffrich R, et al. Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation and chemotherapy. Cancer Res 2005; 65:3643-3655 (Pubitemid 40616341)
11. Abdollahi A, Hlatky L, Huber PE. Endostatin: The logic of antiangiogenic cancer therapy. Drug Resistance Update 2005; 8:59-74. (Pubitemid 40797957)
12. Abdollahi A, Li M, Ping G, Plathow C, Domhan S, Kiessling F, et al. Inhibition of platelet derived growth factor (PDGF) signaling attenuates pulmonary fibrosis. J Exp Med 2005; 201:925-935 (Pubitemid 40524462)
13. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001; 345:517-525
14. Bonner JC. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 2004; 15:255-273
15. Allen JT, Spiteri MA. Growth factors in idiopathic pulmonary fibrosis: relative roles. Respir Res 2002; 3:13.
16. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, et al. Imatinib mesylate inhibits the profibrogenic activity of TGFbeta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004; 114:1308-1316 (Pubitemid 40385302)
17. Chaudhary NI, Roth GJ, Hilberg F, Müller-Quernheim J, Prasse A, Zissel G, et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J 2007; 29:976-985
18. Studer SM, Kaminski N. Towards systems biology of human pulmonary fibrosis. Proc Am Thorac Soc 2007; 4:85-91. (Pubitemid 46084774)
19. Huber PE, Hauser K, Abdollahi A. Genome wide expression profiling of angiogenic signaling and the Heisenberg Uncertainty Principle. Cell Cycle 2004; 3:1348-1351 (Pubitemid 40310663)
20. Koentges G. Evolution of anatomy and gene control. Nature 2008; 451:658-663
21. Wagner GP, Pavlicev M, Cheverud JM. The road to modularity. Nat Rev Genet 2007; 12:921-931